FGFR1 and neoplasm: BGJ398, a highly potent and selective pan-FGFR kinase inhibitor in clinical trials, has demonstrated antitumor activity in advanced cholangiocarcinoma patients with FGFR2 alterations [17] and promoted tumor reductions in FGFR1-amplified breast cancer patients [18].